1
|
Gou ZP, Song ZH, Chen XG, Hu XC, Wang Y, Fan K, Cai YM, Zheng L. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers. CNS Drugs 2019; 33:605-614. [PMID: 31093952 DOI: 10.1007/s40263-019-00628-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Targeted neutrophil inhibitory-hirulog (TNHH) is a novel hybrid glycoprotein that may be a potential drug candidate for acute ischaemic stroke. OBJECTIVE The aim of this study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TNHH in healthy volunteers and thereby determine the dose range for future clinical studies. METHODS This randomized, placebo-controlled study was a single ascending dose design with dose levels of 0.05-1.8 mg/kg (n = 4-6 active, 2 placebos per cohort) in 68 participants. In the TNHH 0.2-1.8 mg/kg and control cohorts, pharmacokinetic and pharmacodynamic blood samples were collected over 168 h after intravenous (IV) administration. TNHH occupancy in peripheral blood neutrophils and blood coagulation were evaluated as the markers of target engagement. RESULTS Two subjects withdrew from the trial before administration of the study treatment, 66 subjects are included in the data analysis. TNHH was well tolerated in all dose regimens. In total, five mild, self-limiting adverse events (AEs) were observed in 4 of the 66 study subjects. Dose-proportional increases in maximum plasma concentration (Cmax) and area under the curve (AUC0-t) of TNHH were observed. Traces of TNHH were excreted in urine. The elimination half-life (t½) ranged from 0.6 to 1.3 h in the eight groups with ascending dose levels. TNHH combined with CD11b/CD18 quickly achieved > 90% receptor occupancy in groups with doses above 0.2 mg/kg. The Cmax and AUC of binding TNHH with CD11b/CD18 increased with the dose. A significant prolongation with dose was observed on thrombin time (TT), and weak influences were observed on prothrombin time (PT) and activated partial thromboplastin time (APTT). CONCLUSION TNHH was well-tolerated following IV infusion. The pharmacokinetic and pharmacodynamic characteristics of TNHH indicate that it merits clinical trials. It is recommended that the single dose of TNHH should be 1.0 mg/kg in future studies, and the expected effect may be achieved after 5-7 days of continuous administration. TRIAL REGISTRATION The study is registered at http://www.chictr.org.cn as ChiCTR-TQR-14004752.
Collapse
Affiliation(s)
- Zhong Ping Gou
- GCP Center, West China Hospital of Sichuan University, Chengdu, 610041, China
| | - Zi Hui Song
- Tianjin Institute of Pharmaceutical Research New Drug Evaluation Co. Ltd, Tianjin, 300301, China
| | - Xiao Gang Chen
- West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, 610041, China
| | - Xiao Cheng Hu
- Tianjin Institute of Pharmaceutical Research New Drug Evaluation Co. Ltd, Tianjin, 300301, China
| | - Ying Wang
- GCP Center, West China Hospital of Sichuan University, Chengdu, 610041, China
| | - Kai Fan
- Chongqing Fagen Biomedical INC., Chongqing, 400010, China
| | - Yong Ming Cai
- Tianjin Institute of Pharmaceutical Research New Drug Evaluation Co. Ltd, Tianjin, 300301, China
| | - Li Zheng
- GCP Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
| |
Collapse
|
2
|
Wilson SJ, Connolly TM, Peters G, Ghosh A, Johnson M, Newby DE. Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis. Cardiovasc Res 2019; 115:669-677. [PMID: 30184110 PMCID: PMC6383059 DOI: 10.1093/cvr/cvy227] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Revised: 08/15/2018] [Accepted: 09/02/2018] [Indexed: 01/06/2023] Open
Abstract
AIMS JNJ-64179375 (hereafter JNJ-9375) is a first-in-class, highly specific, large molecule, exosite 1 thrombin inhibitor. In preclinical studies, JNJ-9375 demonstrated robust antithrombotic protection with a wider therapeutic index when compared to apixaban. The purpose of the present study was to examine for the first time the antiplatelet, anticoagulant and antithrombotic effects of JNJ-9375 in a translational model of ex vivo human thrombosis. METHODS AND RESULTS Fifteen healthy volunteers participated in a double-blind randomized crossover study of JNJ-9375 (2.5, 25, and 250 μg/mL), bivalirudin (6 μg/mL; positive control), and matched placebo. Coagulation, platelet activation, and thrombus formation were determined using coagulation assays, flow cytometry, and an ex vivo perfusion chamber, respectively.JNJ-9375 caused concentration-dependent prolongation of all measures of blood coagulation (prothrombin time, activated partial thromboplastin time, and thrombin time; P < 0.001 for all) and agonist selective inhibition of thrombin (0.1 U/mL) stimulated platelet p-selectin expression (P < 0.001) and platelet-monocyte aggregates (P = 0.002). Compared to placebo, JNJ-9375 (250 μg/mL) reduced mean total thrombus area by 41.1% (95% confidence intervals 22.3 to 55.3%; P < 0.001) at low shear and 32.3% (4.9 to 51.8%; P = 0.025) at high shear. Under both shear conditions, there was a dose-dependent decrease in fibrin-rich thrombus (P < 0.001 for both) but not platelet-rich thrombus (P = ns for both). CONCLUSION Exosite 1 inhibition with JNJ-9375 caused prolongation of blood coagulation, selective inhibition of thrombin-mediated platelet activation, and reductions in ex vivo thrombosis driven by a decrease in fibrin-rich thrombus formation. JNJ-9375 represents a novel class of anticoagulant with potential therapeutic applications.
Collapse
Affiliation(s)
- Simon J Wilson
- British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Room SU305, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SA, UK
| | | | - Gary Peters
- Janssen Research & Development, LLC, Spring House, PA, USA
| | | | | | - David E Newby
- British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Room SU305, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SA, UK
| |
Collapse
|
3
|
Qu Z, Krishnamurthy V, Haller CA, Dorr BM, Marzec UM, Hurst S, Hinds MT, Hanson SR, Liu DR, Chaikof EL. Immobilization of actively thromboresistant assemblies on sterile blood-contacting surfaces. Adv Healthc Mater 2014; 3:30-5. [PMID: 23788402 DOI: 10.1002/adhm.201300110] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2013] [Indexed: 12/13/2022]
Abstract
Rapid one-step modification of thrombomodulin with alkylamine derivatives such as azide, biotin, and PEG is achieved using an evolved sortase (eSrtA) mutant. The feasibility of a point-of-care scheme is demonstrated herein to site-specifically immobilize azido-thrombomodulin on sterilized commercial ePTFE vascular grafts, which exhibit superior thromboresistance compared with commercial heparin-coated grafts in a primate model of acute graft thrombosis.
Collapse
Affiliation(s)
- Zheng Qu
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School and the Wyss Institute of Biologically Inspired, Engineering of Harvard University, Boston, MA 02115, USA; Coulter Department of Biomedical Engineering, Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Qu Z, Muthukrishnan S, Urlam MK, Haller CA, Jordan SW, Kumar VA, Marzec UM, Elkasabi Y, Lahann J, Hanson SR, Chaikof EL. A biologically active surface enzyme assembly that attenuates thrombus formation. ADVANCED FUNCTIONAL MATERIALS 2011; 21:4736-4743. [PMID: 23532366 PMCID: PMC3606904 DOI: 10.1002/adfm.201101687] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Activation of hemostatic pathways by blood-contacting materials remains a major hurdle in the development of clinically durable artificial organs and implantable devices. We postulate that surface-induced thrombosis may be attenuated by the reconstitution onto blood contacting surfaces of bioactive enzymes that regulate the production of thrombin, a central mediator of both clotting and platelet activation cascades. Thrombomodulin (TM), a transmembrane protein expressed by endothelial cells, is an established negative regulator of thrombin generation in the circulatory system. Traditional techniques to covalently immobilize enzymes on solid supports may modify residues contained within or near the catalytic site, thus reducing the bioactivity of surface enzyme assemblies. In this report, we present a molecular engineering and bioorthogonal chemistry approach to site-specifically immobilize a biologically active recombinant human TM fragment onto the luminal surface of small diameter prosthetic vascular grafts. Bioactivity and biostability of TM modified grafts is confirmed in vitro and the capacity of modified grafts to reduce platelet activation is demonstrated using a non-human primate model. These studies indicate that molecularly engineered interfaces that display TM actively limit surface-induced thrombus formation.
Collapse
Affiliation(s)
- Zheng Qu
- Departments of Biomedical Engineering and Surgery, Georgia Institute of Technology and Emory University Atlanta, GA 30322 (USA)
| | - Sharmila Muthukrishnan
- Departments of Biomedical Engineering and Surgery, Georgia Institute of Technology and Emory University Atlanta, GA 30322 (USA)
| | - Murali K. Urlam
- Departments of Biomedical Engineering and Surgery, Georgia Institute of Technology and Emory University Atlanta, GA 30322 (USA)
| | - Carolyn A. Haller
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, and the Wyss Institute of Biologically Inspired Engineering of Harvard University Boston, MA 02115 (USA)
| | - Sumanas W. Jordan
- Departments of Biomedical Engineering and Surgery, Georgia Institute of Technology and Emory University Atlanta, GA 30322 (USA)
| | - Vivek A. Kumar
- Departments of Biomedical Engineering and Surgery, Georgia Institute of Technology and Emory University Atlanta, GA 30322 (USA)
| | - Ulla M. Marzec
- Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006 (USA)
| | - Yaseen Elkasabi
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109 (USA)
| | - Joerg Lahann
- Department of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109 (USA)
| | - Stephen R. Hanson
- Oregon National Primate Research Center, Oregon Health and Science University Beaverton, OR 97006 (USA)
| | - Elliot L. Chaikof
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, and the Wyss Institute of Biologically Inspired Engineering of Harvard University Boston, MA 02115 (USA)
| |
Collapse
|
5
|
Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw SY, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 1996; 94:1412-22. [PMID: 8823001 DOI: 10.1161/01.cir.94.6.1412] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Thrombolytic therapy reduces mortality in patients with acute myocardial infarction, but significant limitations exist with the use of currently available agents. In the present report, we describe the thrombolytic and antithrombotic potencies of a hybrid recombinant plasminogen activator consisting of an antifibrin antibody 59D8 (AFA) and low-molecular-weight single-chain urokinase-type plasminogen activator (scuPA). METHODS AND RESULTS A thrombolysis model in which thrombi are preformed in vivo in juvenile baboons was developed to compare the potencies of AFA-scuPA, recombinant tissue plasminogen activator (rTPA), and recombinant scuPA (rscuPA) in lysing nonocclusive 111In-labeled platelet-rich arterial-type thrombi and 125I-labeled fibrin-rich venous-type thrombi. Systemic infusion of 1.89 nmol/kg AFA-scuPA produced thrombolysis that was comparable to that obtained with much higher doses of TPA (14.2 nmol/kg) and rscuPA (28.5 nmol/kg). When steady-state plasma concentrations are normalized, AFA-scuPA lyses thrombi sixfold more rapidly than scuPA and TPA (P < .001) and reduces the rate of formation more than comparable doses of rscuPA (P < .0001). At equivalent thrombolytic doses, AFA-scuPA produced fewer antihemostatic effects than either rTPA or rscuPA. Template bleeding time measurements were shorter (3.5 +/- 0.12 minutes for AFA-scuPA versus 5.3 +/- 0.36 and 5.2 +/- 0.04 minutes for rTPA and rscuPA, respectively; P < .05), alpha 2-antiplasmin consumption was less (P < .05), and D-dimer generation was lower (P < .05). CONCLUSIONS We conclude that antibody targeting of scuPA to fibrin increases thrombolytic and antithrombotic potencies with less impairment of hemostasis compared with rTPA and rscuPA.
Collapse
Affiliation(s)
- M S Runge
- Cardiology Division, University of Texas Medical Branch, Galveston 77555-0553, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995; 92:727-33. [PMID: 7641350 DOI: 10.1161/01.cir.92.4.727] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Direct thrombin inhibitors are a new class of drugs that may offer a more effective and potentially simpler alternative to heparin. Hirulog is a synthetic peptide based on the leech-derived compound hirudin and, like hirudin, is a highly specific, direct inhibitor of free and clot-bound thrombin. METHODS AND RESULTS TIMI 7 was a randomized, double-blind study of Hirulog, given with 325 mg/d aspirin to 410 patients with unstable angina. Patients received a constant infusion of Hirulog for 72 hours at one of four doses: 0.02 (n = 160), 0.25 (n = 81), 0.5 (n = 88), and 1.0 (n = 81) mg.kg-1.h-1. The primary efficacy end point was "unsatisfactory outcome," defined as death, nonfatal myocardial infarction (MI), rapid clinical deterioration, or recurrent ischemic pain at rest with ECG changes by 72 hours. Unsatisfactory outcome was not different among the four dose groups: 8.1%, 6.2%, 11.4%, and 6.2% (P = NS). However, the secondary end point of death or nonfatal MI through hospital discharge occurred in 10.0% of patients treated with 0.02 mg.kg-1.h-1 compared with 3.2% of patients treated with the three higher doses of Hirulog (0.25, 0.5, and 1.0 mg.kg-1.h-1, P = .008). Only 2 of 410 patients (0.5%) experienced a major hemorrhage attributed to Hirulog. CONCLUSIONS The direct thrombin inhibitor Hirulog is a promising new antithrombotic agent that deserves further study. The results of TIMI 7 lend support to the use of an antithrombin agent with aspirin in patients with unstable angina.
Collapse
Affiliation(s)
- J Fuchs
- Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA
| | | |
Collapse
|
7
|
Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation 1995; 92:485-91. [PMID: 7634464 DOI: 10.1161/01.cir.92.3.485] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Since activated factor X (FXa) has a central role in hemostasis and thrombosis, it is an attractive target for antithrombotic strategies. Accordingly, we evaluated the relative antihemostatic and antithrombotic effects of an orally active amidinoaryl propanoic acid inhibitor of FXa, APAP, in baboons. METHODS AND RESULTS With a two-component thrombogenic device that induced the concurrent formation of both arterial-type platelet-rich and venous-type fibrin-rich thrombus when interposed in chronic exteriorized arteriovenous (AV) femoral shunts flowing at 40 mL/min, thrombus formation was compared for oral versus parenteral APAP by measurement of 111In-platelet deposition, 125I-fibrin accumulation, thrombotic obstruction of flow, and circulating levels of blood biochemical markers of thrombosis. The direct infusion of APAP (120 micrograms/min) into AV shunts proximal to thrombogenic devices for 1 hour achieved local drug levels of 4.3 +/- 0.4 mg/L and substantially reduced the accumulation of platelets and fibrin in the formation of venous-type fibrin-rich thrombus (P < .01) but not in the formation of platelet-rich arterial-type thrombus (P > .1). APAP was subsequently removed from plasma with plasma clearance rates of T50 alpha of 6.3 minutes and T50 beta of 99 minutes. The oral administration of APAP (50 mg/kg) produced peak plasma levels of 3.7 +/- 1.4 micrograms/mL at 30 minutes and gradually declining plasma levels over about 6 to 8 hours, with bioavailability estimated to be approximately 5% to 12%. Oral APAP decreased platelet deposition (P < .01) and fibrin accumulation (P < .05) in venous-type thrombus but failed to decrease platelet or fibrin accumulation in arterial-type thrombus (P > .1 in both cases). Oral and infused APAP prolonged the activated partial thromboplastin time and prevented thrombus-dependent elevations in plasma fibrinopeptide A, thrombin-antithrombin III complex, beta-thromboglobulin, and platelet factor 4 levels. Additionally, APAP produced dose-dependent inhibition of FXa bound to thrombus on segments of vascular graft interposed in exteriorized AV shunts for 15 minutes. CONCLUSIONS An oral synthetic antagonist of FXa, APAP, inhibits the formation of venous-type fibrin-rich thrombus by inactivating bound and soluble FXa without impairing platelet hemostatic function.
Collapse
Affiliation(s)
- T Yokoyama
- Division of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | | | | | |
Collapse
|
8
|
Abstract
Platelet activation plays a critical role in thromboembolic disorders, and aspirin remains a keystone in preventive strategies. This remarkable efficacy is rather unexpected, as aspirin selectively inhibits platelet aggregation mediated through activation of the arachidonic-thromboxane pathway, but not platelet aggregation induced by adenosine diphosphate (ADP), collagen and low levels of thrombin. This apparent paradox has stimulated investigations on the effect of aspirin on eicosanoid-independent effects of aspirin on cellular signalling. It has also fostered the search for antiplatelet drugs inhibiting platelet aggregation at other levels than the acetylation of platelet cyclo-oxygenase, such as thromboxane synthase inhibitors and thromboxane receptor antagonists. The final step of all platelet agonists is the functional expression of glycoprotein (GP) IIb/IIIa on the platelet surface, which ligates fibrinogen to link platelets together as part of the aggregation process. Agents that interact between GPIIb/IIIa and fibrinogen have been developed, which block GPIIb/IIIa, such as monoclonal antibodies to GPIIb/IIIa, and natural and synthetic peptides (disintegrins) containing the Arg-Gly-Asp (RGD) recognition sequence in fibrinogen and other adhesion macromolecules. Also, some non-peptide RGD mimetics have been developed which are orally active prodrugs. Stable analogues of prostacyclin, some of which are orally active, are also available. Thrombin has a pivotal role in both platelet activation and fibrin generation. In addition to natural and recombinant human antithrombin III, direct antithrombin III-independent thrombin inhibitors have been developed as recombinant hirudin, hirulog, argatroban, boroarginine derivatives and single stranded DNA oligonucleotides (aptanes). Direct thrombin inhibitors do not affect thrombin generation and may leave some 'escaping' thrombin molecules unaffected. Inhibition of factor Xa can prevent thrombin generation and disrupt the thrombin feedback loop that amplifies thrombin production.
Collapse
Affiliation(s)
- M Verstraete
- Center for Molecular and Vascular Biology, University of Leuven, Belgium
| | | |
Collapse
|
9
|
Maksimenko AV. Experimental combined thrombolytic therapy: The current position and directions of progress (review). Pharm Chem J 1994. [DOI: 10.1007/bf02219399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
|
11
|
|
12
|
Abstract
Life-threatening thrombo-occlusive events producing heart attacks and strokes develop in patients at sites of atherosclerotic arterial stenoses when plaques rupture, a process resistant to both aspirin and heparin. Resistant thrombotic complications are also troublesome during therapeutic thrombolytic or mechanical interventions for symptomatic atherosclerotic vascular disease, including angioplasty, various types of atherectomies, endarterectomy, endovascular stent deployment, or implanted small caliber vascular grafts. In this review therapeutic strategies for more effective management of these resistant, platelet-dependent, occlusive thrombi are discussed, including: a) inhibition of platelet recruitment by anti-GPIIb/IIIa monoclonal antibodies, naturally occurring peptides containing RGD sequences, or synthetic competitive analogs; b) direct inactivation of thrombin bound to thrombus by natural or synthetic antithrombin peptides; c) interruption of thrombin's production by natural or synthetic antagonists of Factor Xa or extrinsic and intrinsic coagulation pathways; and d) elimination of thrombogenicity at sites of vascular injury by immediately restoring confluent endothelium or prior therapy with dietary n-3 fatty acids. However, antagonists of both GPIIb/IIIa- and thrombin-dependent platelet recruitment produce equivalent inhibition of thrombus formation and platelet hemostatic function. Interestingly, hemostasis is spared by therapies that inhibit thrombin's production. Recommendations for development strategies are related to the relative hemostatic risks and antithrombotic benefits.
Collapse
Affiliation(s)
- L A Harker
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322
| |
Collapse
|
13
|
Herrman JP, Serruys PW. Thrombin and antithrombotic therapy in interventional cardiology. Tex Heart Inst J 1994; 21:138-47. [PMID: 8061538 PMCID: PMC325149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Despite developments in percutaneous transluminal coronary angioplasty, the success of this treatment method remains clouded by early and late reocclusion. Increased experience, advances in technology, and the introduction of adjunctive devices have contributed to a higher procedural success rate (90% to 95%) and to a lower complication rate (4% to 5%), in spite of the expanded indications for angioplasty. Late renarrowing of the treated coronary artery, in combination with recurrence of angina pectoris, occurs in 15% to 40% of angioplasty patients. Several multicenter randomized trials of pharmaceutical agents have been conducted or are in progress, in an effort to diminish the rate of late reocclusion. No major breakthrough has been reported, although a clear progression has been made in the understanding of the restenosis phenomenon. It is evident that thrombin plays a detrimental role in the vascular wall injury resulting from angioplasty procedures. Current pharmacologic research concentrates on direct inhibition of prothrombin conversion and thrombus formation. Animal experimental work in this field is encouraging, and the results of clinical trials will elucidate important questions about the safety, efficacy, and immuno-allergic potential of modern antithrombotic medication.
Collapse
Affiliation(s)
- J P Herrman
- Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands
| | | |
Collapse
|
14
|
Cadroy Y, Hanson SR, Harker LA. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates. ARTERIOSCLEROSIS AND THROMBOSIS : A JOURNAL OF VASCULAR BIOLOGY 1993; 13:1213-7. [PMID: 8343496 DOI: 10.1161/01.atv.13.8.1213] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Dermatan sulfate (DS), a factor that amplifies plasma heparin cofactor II antithrombin (HCII) activity, has been evaluated in baboons for its relative antithrombotic and antihemostatic effects by use of a model that combines both platelet-rich and fibrin-rich thrombus formation. Thrombus was generated in a two-component thrombogenic device incorporated into exteriorized femoral arteriovenous shunts, in which a proximal segment of collagen-coated tubing induces platelet-rich arterial-type thrombus and distal expanded chambers with disturbed and static flow produce fibrin-rich venous-type thrombus. Thrombus formation was measured as the deposition of autologous 111In-platelets by imaging analysis and by the accumulation of 125I-fibrin. Intravenous infusion of DS at 0.83, 8.3, and 42 mg/kg maintained plasma levels at approximately 7, 70, and 400 micrograms/mL, respectively, throughout the period of study. By enhancing HCII-dependent inactivation of soluble thrombin, DS prolonged the coagulation times, reduced plasma fibrinopeptide A levels, and decreased fibrin-rich thrombus formation in the chamber portion of the device in a dose-dependent manner, ie, the intermediate dose reduced fibrin accumulation by approximately 70% (P < .05). By contrast, neither platelet deposition on collagen nor platelet hemostatic function, assessed with bleeding time determinations, was significantly affected by DS at any dose studied (P > .2 and P > .1, respectively, for the high dose), a finding presumably explained by the resistance of immobilized thrombin to inactivation by DS.
Collapse
Affiliation(s)
- Y Cadroy
- Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Hôpital Purpan, Toulouse, France
| | | | | |
Collapse
|
15
|
Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci U S A 1992; 89:6040-4. [PMID: 1385867 PMCID: PMC49433 DOI: 10.1073/pnas.89.13.6040] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
To determine in vivo functional roles for thrombin's structural domains, we have compared the relative antithrombotic and antihemostatic effects of (i) catalytic-site antithrombin peptide, D-Phe-Pro-Arg; (ii) exosite antithrombin peptide, the C-terminal tyrosine-sulfated dodecapeptide of hirudin; and (iii) bifunctional antithrombin peptide, a 20-mer peptide combining catalytic-site antithrombin peptide and exosite antithrombin peptide with a polyglycyl linker. All three peptides inhibited thrombin-mediated platelet aggregation and fibrin formation in vitro. In vivo thrombus formation was measured in real time as 111In-labeled platelet deposition and 125I-labeled fibrin accumulation on thrombogenic segments incorporated into chronic exteriorized arteriovenous access shunts in baboons. Under low flow conditions, the continuous infusion of peptides reduced thrombus formation onto collagen-coated tubing by half at doses (ID50) and corresponding concentrations (IC50) of 800 nmol per kg per min and 400 nmol/ml for catalytic-site antithrombin peptide, greater than 1250 nmol per kg per min and greater than 1500 mumol/ml for exosite antithrombin peptide, and 50 nmol per kg per min and 25 nmol/ml for bifunctional antithrombin peptide. Under arterial flow conditions, systemically administered bifunctional antithrombin peptide decreased thrombus formation in a dose-dependent manner for segments of collagen-coated tubing or prosthetic vascular graft ID50 and IC50 values of 120 nmol per kg per min and 15 nmol/ml; this dose also produced intermediate inhibition of hemostatic function [bleeding time, 21 +/- 3 min vs. 4.5 +/- 0.5 min (baseline values); P less than 0.001; activated partial thromboplastin time, 285 +/- 13 sec vs. 31 +/- 3 sec (baseline), P less than 0.001]. In contrast, thrombus formation onto segments of endarterectomized aorta was potently decreased by bifunctional antithrombin peptide with an ID50 value of 2.4 nmol per kg per min and an IC50 value of 0.75 nmol/ml, a systemic dose that failed to affect hemostasis. Thus, inhibiting both thrombin's catalytic and exosite domains increases antithrombotic potency by several orders of magnitude over the inhibition of either domain alone, particularly at sites of deep arterial injury.
Collapse
Affiliation(s)
- A B Kelly
- Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322
| | | | | | | | | |
Collapse
|
16
|
Chapter 11. Future Antithrombotic Therapy. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1992. [DOI: 10.1016/s0065-7743(08)60409-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|